Trials / Unknown
UnknownNCT05353361
A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
A Phase Ib/II Multicenter, Open-Label Clinical Trial of SHR-A1811 Injection in Combination With Pyrotinib or Pertuzumab or Adebrelimab or Paclitaxel for Injection (Albumin Bound) in Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 402 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811：Pyrotinib | SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral |
| DRUG | SHR-A1811；Pertuzumab | SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip |
| DRUG | SHR-A1811；Adebrelimab | SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip |
| DRUG | SHR-A1811；Albumin paclitaxel | SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip |
Timeline
- Start date
- 2022-05-23
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2022-04-29
- Last updated
- 2023-09-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05353361. Inclusion in this directory is not an endorsement.